| ABSTRACT……………………………………………………………………………………………………………………………………………………………………………….…. |
679 |
| 1. BACKGROUND AND PURPOSE………………………………………………………………………………………………………………………………………………… |
679 |
| 1.1 Current dietary sodium pattern in Taiwan and worldwide……………………………………………………………………………………………… |
679 |
| 1.2 Health impact of excessive sodium intake……………………………………………………………………………………………………………………… |
680 |
| 1.3 Need for collaborative action…………………………………………………………………………………………………………………………………………. |
685 |
| 2. CURRENT STATUS OF SALT REDUCTION CAMPAIGNS WORLDWIDE……………………………………………………………………………………….. |
686 |
| 2.1 Salt reduction initiatives and their impact on heart health…………………………………………………………………………………………….. |
686 |
| 2.2 Overview of international guidelines……………………………………………………………………………………………………………………………… |
686 |
| 2.3 Evidence and recommendations for daily salt and potassium intake……………………………………………………………………………… |
687 |
| 3. STAKEHOLDER ROLES AND RESPONSIBILITIES………………………………………………………………………………………………………………………… |
689 |
| 3.1. Academic institutions: research and evidence………………………………………………………………………………………………………………. |
689 |
| 3.2. Medical associations: clinical guidelines………………………………………………………………………………………………………………………… |
689 |
| 3.3. Industry partners: product reformulation……………………………………………………………………………………………………………………… |
690 |
| 3.4. Government agencies: policy framework……………………………………………………………………………………………………………………… |
690 |
| 4. ACTION PLAN AND GOALS……………………………………………………………………………………………………………………………………………………… |
691 |
| 4.1 Short-, medium-, and long-term goals……………………………………………………………………………………………………………………………. |
691 |
| 4.2 Public education campaigns…………………………………………………………………………………………………………………………………………… |
691 |
| 4.3 Industry collaboration strategies……………………………………………………………………………………………………………………………………. |
692 |
| 4.4 Healthcare provider engagement…………………………………………………………………………………………………………………………………… |
693 |
| 4.5 Monitoring, evaluation, and accountability……………………………………………………………………………………………………………………. |
694 |
| 4.6 Economic impact assessment………………………………………………………………………………………………………………………………………… |
697 |
| 4.7 Implementation challenges, risks, and mitigation strategies in Taiwan………………………………………………………………………….. |
697 |
| 4.8 Safe adoption of potassium-enriched salt substitutes: risk stratification and clinical considerations……………………………… |
698 |
| 5. CONSENSUS STATEMENT……………………………………………………………………………………………………………………………………………………….. |
698 |
| ACKNOWLEDGMENT…………………………………………………………………………………………………………………………………………………………………. |
699 |
| DECLARATION OF CONFLICT OF INTEREST…………………………………………………………………………………………………………………………………. |
700 |
| AUTHOR CONTRIBUTIONS…………………………………………………………………………………………………………………………………………………………. |
700 |
| REFERENCES………………………………………………………………………………………………………………………………………………………………………………. |
700 |
